PMID- 25369141
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20150204
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 17
IP  - 2
DP  - 2015 Feb
TI  - Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a 
      meta-analysis.
PG  - 142-8
LID - 10.1089/dia.2014.0190 [doi]
AB  - BACKGROUND: Insulin is an essential therapy for patients with type 1 diabetes 
      mellitus (T1DM). With the progression of the disease, many patients with T1DM may 
      have an increased prevalence of insulin resistance; thus the common standard 
      insulin therapy requires a high insulin dosage (>1 unit/kg/day) and is usually 
      associated with many side effects. Studies have shown that metformin may benefit 
      those insulin-resistant individuals with T1DM. This meta-analysis was performed 
      to provide the evidence of clinical efficacy and safety of metformin in T1DM. 
      MATERIALS AND METHODS: We conducted a search on Medline, EMBASE, and the Cochrane 
      Library for relevant studies published before May 2014 based on "metformin" and 
      "diabetes mellitus, type 1." The following outcomes were evaluated: hemoglobin 
      A1c (HbA1c), fasting plasma glucose (FPG), lipid metabolism, weight, insulin 
      dosage, hypoglycemia, diabetic ketoacidosis, or gastrointestinal adverse events 
      (AEs). The meta-analysis was performed using Review Manager version 5.2 software 
      (The Nordic Cochrane Centre, Copenhagen, Denmark). RESULTS: In total, eight 
      randomized controlled trials were included. Metformin was associated with a 
      reduction in daily insulin dosage, body weight, total cholesterol level, 
      low-density lipoprotein level, and high-density lipoprotein level but an increase 
      in risk of gastrointestinal AEs compared with placebo treatment in T1DM patients. 
      No significant difference was found between the metformin group and the placebo 
      group in HbA1c level, FPG level, or triglycerides level. No significant 
      difference was found between the metformin group and the placebo group in the 
      risk of severe hypoglycemia or diabetic ketoacidosis. CONCLUSIONS: Metformin may 
      decrease the daily insulin dosage, body weight, and lipid levels in T1DM. 
      However, metformin does not increase the incidence of hypoglycemia and 
      ketoacidosis. High-quality, large-sample, and long-term follow-up clinical trials 
      are needed to confirm these conclusions.
FAU - Liu, Cong
AU  - Liu C
AD  - 1 NO.2 Department of Endocrinology, Shengjing Hospital of China Medical 
      University , Shenyang, Liaoning, People's Republic of China .
FAU - Wu, Dan
AU  - Wu D
FAU - Zheng, Xuan
AU  - Zheng X
FAU - Li, Ping
AU  - Li P
FAU - Li, Ling
AU  - Li L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20141104
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 1/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Resistance
MH  - Metformin/*therapeutic use
MH  - Treatment Outcome
EDAT- 2014/11/05 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/11/05 06:00
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1089/dia.2014.0190 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2015 Feb;17(2):142-8. doi: 10.1089/dia.2014.0190. Epub 
      2014 Nov 4.